Novo Nordisk A/S (NVO) FinancialsNVOFinancialNovo Nordisk A/S

Novo Nordisk A/S (NVO) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Total GLP-1, accounting for 46.9% of total sales, equivalent to $5.72B. Other significant revenue streams include Obesity (Wegovy®) and Fast-acting insulin. Understanding this composition is critical for investors evaluating how NVO navigates market cycles within the Pharmaceuticals industry.

Evaluating the bottom line, Novo Nordisk A/S maintains a gross margin of 78.21%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 43.01%, while the net margin is 26.74%. These profitability ratios, combined with a Return on Equity (ROE) of 60.34%, provide a clear picture of how effectively NVO converts its operational activities into shareholder value.

In the context of the broader market, NVO competes directly with industry leaders such as LLY and RDY. With a market capitalization of $203.65B, it holds a significant position in the sector. When comparing efficiency, NVO's gross margin of 78.21% stands against LLY's 85.78% and RDY's 46.52%. Such benchmarking helps identify whether Novo Nordisk A/S is trading at a premium or discount relative to its financial performance.

Novo Nordisk's recent financial performance shows a mixed picture. The gross margin for Q2 2026 is at 78.21%, which is strong but down from previous quarters. The net income for Q1 2026 was $7.61 billion, but it dropped to $3.26 billion in Q2 2026, indicating volatility in earnings.